Cholesterol uptake capacity

1. Cholesterol uptake capacity has no effect on acute myocardial infarction in humans (1.11 ± 0.45 vs. 1.16 ± 0.55, p = 0.6).

   “non-significantly lower in the non-AMI vs. AMI group (1.11 ± 0.45 vs. 1.16 ± 0.55; p = 0.6)”

   Humansserum

   Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study

   Journal of diabetes and metabolic disorders·3 Mar 2026

More on Acute myocardial infarction

1. Cholesterol uptake capacity has no effect on coronary artery disease in humans (1.18 ± 0.58 vs. 1.09 ± 0.42, p = 0.3).

   “non-significantly higher in the non-CAD vs. CAD group (1.18 ± 0.58 vs. 1.09 ± 0.42; p = 0.3).”

   Humansserum

   Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study

   Journal of diabetes and metabolic disorders·3 Mar 2026

More on Coronary artery disease

1. Cholesterol uptake capacity has no effect on cardiovascular disease in humans (1.19 ± 0.58 vs. 1.08 ± 0.42, p = 0.2).

   “Serum HDL CUC was non-significantly higher in the non-CVD group compared with CVD patients (1.19 ± 0.58 vs. 1.08 ± 0.42; p = 0.2)”

   Humansserum

   Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study

   Journal of diabetes and metabolic disorders·3 Mar 2026

More on Cardiovascular disease

1. Cholesterol uptake capacity lowers the risk of stroke in humans (OR 0.31, 95% CI 0.11-0.90).

   “HDL CUC showed a significant decrease in the stroke vs. non-stroke group (0.09 ± 0.30 vs. 1.17 ± 0.54; p = 0.05; odds ratio 0.31, 95% confidence interval 0.11-0.90; p = 0.03).”

   Humansserum

   Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study

   Journal of diabetes and metabolic disorders·3 Mar 2026

More on Stroke